Quantitative confocal spectral imaging analysis of mitoxantrone within living K562 cells: Intracellular accumulation and distribution of monomers, aggregates, naphthoquinoxaline metabolite, and drug-target complexes

被引:50
作者
Feofanov, A
Sharonov, S
Fleury, F
Kudelina, I
Nabiev, I
机构
[1] UNIV REIMS,UFR PHARM,LAB SPECT BIOMOL,F-51096 REIMS,FRANCE
[2] RUSSIAN ACAD SCI,SHEMYAKIN & OVCHINNIKOV INST BIOORGAN CHEM,MOSCOW 117871,RUSSIA
基金
俄罗斯基础研究基金会;
关键词
D O I
10.1016/S0006-3495(97)78357-7
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Confocal spectral imaging (CSI) technique was used for quantitative analysis of the uptake, subcellular localization, and characteristics of localized binding and retention of anticancer agent mitoxantrone (MITOX) within human K562 erythroleukemia cells. The CSI technique enables identification of the state and interactions of the drug within the living cells. Utilizing this unique property of the method, intracellular distributions were examined for monomeric MITOX in polar environment, MITOX bound with hydrophobic cellular structures, naphthoquinoxaline metabolite, and nucleic acid-related complexes of MITOX. The features revealed were compared for the cells treated with 2 mu M or 10 mu M of MITOX for 1 h and correlated to the known data on antitumor action of the drug. MITOX was found to exhibit high tendency to self-aggregation within intracellular media. The aggregates are concluded to be a determinant of long-term intracellular retention of the drug and a source of persistent intracellular binding of MITOX. Considerable penetration of MITOX in the hydrophobic cytoskeleton structures as well as growing accumulation of MITOX bound to nucleic acids within the nucleus were found to occur in the cells treated with a high concentration of the drug. These effects may be among the factors stimulating and/or accompanying high-dose mitoxantrone-induced programmed cell death or apoptosis.
引用
收藏
页码:3328 / 3336
页数:9
相关论文
共 30 条
  • [1] ARLIN Z, 1990, LEUKEMIA, V4, P177
  • [2] BASRA J, 1985, ANTI-CANCER DRUG DES, V1, P45
  • [3] BHALLA K, 1993, BLOOD, V82, P3133
  • [4] BLANZ J, 1991, DRUG METAB DISPOS, V19, P871
  • [5] CAPRANICO G, 1995, CURRENT PHARM DESIGN, V1, P1
  • [6] CORBETT AH, 1993, CHEM RES TOXICOL, V6, P586
  • [7] DAGRA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163
  • [8] PHARMACOKINETICS AND METABOLISM OF MITOXANTRONE - A REVIEW
    EHNINGER, G
    SCHULER, U
    PROKSCH, B
    ZELLER, KP
    BLANZ, J
    [J]. CLINICAL PHARMACOKINETICS, 1990, 18 (05) : 365 - 380
  • [9] EHNINGER G, 1986, CANCER TREAT REP, V70, P1373
  • [10] MITOXANTRONE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL IN THE CHEMOTHERAPY OF CANCER
    FAULDS, D
    BALFOUR, JA
    CHRISP, P
    LANGTRY, HD
    [J]. DRUGS, 1991, 41 (03) : 400 - 449